CYTOFOTC

Altamira Therapeutics Ltd.

Healthcare·Ophthalmology·Commercial·Hamilton, Bermuda
OphthalmologyInfectious Disease

Altamira Therapeutics Ltd. (CYTOF): 2 pipeline candidates. Updated within the last hour.

7.8/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.9

D/E 0.75 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Altamira Therapeutics Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$343K

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (2 candidates)

DrugPhase
bentriotm allergy blocker—
ciprofloxacinApproved
·CEO: Dr. Thomas Meyer Ph.D.

Frequently asked questions

How many drug candidates are in Altamira Therapeutics Ltd.'s pipeline?

Altamira Therapeutics Ltd. (CYTOF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Altamira Therapeutics Ltd.'s market capitalization?

Altamira Therapeutics Ltd.'s market capitalization is approximately $343K.

Who is the CEO of Altamira Therapeutics Ltd.?

Dr. Thomas Meyer Ph.D. is the chief executive officer of Altamira Therapeutics Ltd. (CYTOF).

Get the full picture on Altamira Therapeutics Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar